Our case studies showcase how we help biotech and life science companies turn scientific potential into tangible value. From early-stage financing to strategic partnerships, each example illustrates how our Strategy & Value Architecture and Capital & Transactions pillars work together to unlock funding, de‑risk development, and align investors and pharma partners around a clear value story.
Securing Series A Capital for an Oncology Asset
€18.5M Series A Funding successfully closed with a consortium of two lead European Life Science funds within 7 months, securing the runway for clinical validation.
The Challenge
A European preclinical biotech company developed a novel small-molecule platform for hard-to-treat cancers. To enter Phase I clinical trials, they needed a €20M Series A round but struggled to communicate their complex biological mechanism of action to non-scientific financial investors.
Our Pillars in Action
1. Strategy & Value Architecture: We translated their complex laboratory and animal model data into a crystal-clear Target Product Profile (TPP), highlighting the commercial asset value and defining the exact regulatory path.
2. Capital & Transactions: We bypassed the gatekeepers and introduced the founders directly to our network of specialized Life Science VCs, managing the entire transaction and data room preparation.
Cross-Border Out-Licensing & Strategic Pharma Partnership
Secured a €15M non-dilutive upfront payment combined with up to €180M in clinical/commercial milestones and tiered royalties, executing a high-value strategic alliance with a global Pharma leader.
The Challenge
A platform biotech startup holding a valuable, validated gene-therapy asset was facing a cash crunch. Instead of raising dilutive venture capital in a tough market, the founders wanted to secure a major corporate partnership but lacked direct access to global Big Pharma decision-makers.
Our Pillars in Action
1. Strategy & Value Architecture: We unbundled their platform, showcasing the massive immediate value of their lead asset while protecting the long-term value of the underlying platform technology.
2. Capital & Transactions: We leveraged our trusted relationships with global top-20 pharmaceutical corporations and orchestrated a competitive bidding process among corporate venture and business development teams.
Institutional Growth Funding for an Immunology Pipeline
€43M Series B Round secured (co-led by a US healthcare fund and a European VC) and flawless execution of the Phase II trial launch, keeping the project ahead of schedule.
The Challenge
A clinical-stage biotech firm with a promising Phase I asset in immunology needed a massive €40M Series B round to fund parallel Phase II trials. International investors harbored doubts regarding the trial design, endpoint selection, and future pricing against established biologics.
Our Pillars in Action
1. Strategy & Value Architecture: We re-architected their clinical development roadmap and built a robust commercial value framework that proved the asset's superiority to future payers.
3. Execution, Transformation & Scale: Post-transaction, we stayed on board to transform their lean R&D setup into a high-performance clinical operations organization, optimizing trial timelines and investigator site selection.